Page 5 - Slide 1
P. 5
Amgen Bone Health Mentoring Program
Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN
1026 Blosozumab, a Humanized Monoclonal Antibody
against sclerostin, demonstrated Anabolic Effects on
Bone in Postmenopausal Women.
McColm J, Womack T, Hu L, et al.
Session: Concurrent Oral Session 05: John H. Carsten's
Memorial Session for Osteoporosis Treatment ◼
Saturday, October 13 09:45 AM - 10:00 AM ◼
Auditorium-Main/Minneapolis Convention Center
Results Abstract Information Additional Notes from
Poster/Presentation*
Conclusions ▪ While single-dose was associated with
Implications up to 3.41% increase in LS BMD from Updated/Additional Data,
for Canadian baseline at day 85, multiple Key Takeaways
administration of blosozumab was
Practice associated with up to 7.71% increase
in LS BMD.
▪ The effects were dose related over the
tested range and were largely
independent of prior ALN use.
▪ In both the studies, blosozumab was
well tolerated with no safety concerns .
▪ Significant bone biomarker responses
were observed in sclerostin, P1NP,
BSAP, OC, and CTx.
▪ There were no indications of
neutralizing effects on PK/PD
parameters.
▪ The promising early results warrant
further evaluation of blosozumab as an
anabolic therapy for osteoporosis.
Discussion Points, Key Takeaways
